Kornimate/medical-research-clean huggingface dataset:
study of the analytical performance of different salivary self-collection methods for the detection of covid-19

Conditions: SARS-CoV Infection

Summary: since march 2020, the sars-cov type coronavirus infection (sars-cov-2; ncov19; covid-19) is considered pandemic. as early as april 2020, the world health organization recommended the implementation of mass screening of populations, with the aim of identifying cases and contacts and controlling viral spread. since the end of lock-down on may 11, 2020,the screening policy has been intensified to fight against covid-19. virological tests by rt-pcr are thus accessible to all, without a prescription and reimbursed by health insurance. the french government has also set a quantitative target of 1 million tests per week. in order to meet this target, the number of sampling centers has been increased (mobile structures, etc.). screening tests are currently carried out using a nasopharyngeal swab analyzed by rt-pcr for the detection of viral rna. this type of sample has several technical and logistic constraints. it must be carried out by personnel who are authorized and trained in this procedure and in appropriate hospital hygiene practices. it exposes the sampling personnel to possible contamination through nasopharyngeal secretions or coughing that may occur during sampling. with the increase in screening, there are sometimes insufficient numbers of sampling personnel and there is significant market pressure for swabs and virological transport media. in addition, these swabs are uncomfortable or even painful for the patient, which could imply a reluctance to be screened. they are also complicated in children, whether they are rhino- or oropharyngeal. an alternative to the nasopharyngeal swab, which is the subject of this project, would be to have one or more reliable sampling methods that are less restrictive than the nasopharyngeal swab ("gold standard"). thus, we propose to test and compare the results obtained by molecular biology techniques on nasopharyngeal, salivary and buccal swabs.


Eligibility criteria:
inclusion criteria: * to be at least 18 years of age * to come at hospital for sars-cov-2 screening * to be able to receive a nasopharyngeal swab exclusion criteria: * people under 18 years of age * inpatient in intensive care * pregnant or breastfeeding woman * individual with dry syndrome (gougerot-sjögren syndrome) * taking treatments that reduce salivary volume (anticholinergic activity) * people with a covid-19 diagnosis confirmed by a molecular biology method \>7 days ago * contraindication to oral swabbing
omega 3 polyunsaturated fatty acid supplements (pufas) and microvolt t wave alternans (twa) in patients with ventricular arrhythmia

Conditions: Arrhythmia; Defibrillators, Implantable

Summary: this is a hypothesis testing study, the hypothesis being that dietary supplements of n-pufas concentrates are anti-arrhythmic in ventricular arrhythmic substrates. study aims: to investigate whether dietary supplements of n-3 polyunsaturated fatty acid concentrates (2g pufas/day, omacor) reduces mtwa (a surrogate endpoint for ventricular arrhythmia substrate) in patients with icds for malignant ventricular arrhythmias.

patients from the department of cardiology icd out-patient clinic, ninewells hospital and medical school, will be recruited. all these patients have a history of documented ventricular arrhythmia. data from previous studies predict that 90% of these patients will have abnormal mtwa. a total of 45 icd patients will be recruited. the study design will be a double blind randomised placebo controlled crossover design. a baseline mtwa test will be performed and patients with an abnormal test will be selected. the patients will be randomised to receive fish oil supplements (2g/day) or placebo for 8 weeks each. at the end of each intervention period, a repeat mwta test will be performed. a 10 ml venous blood sampled will also be collected at baseline, and after each intervention period (3 samples in total). patients in atrial fibrillation, frequent atrial or ventricular ectopics, or with ventricular pacing from the icd, unstable angina, nyha iv heart failure, pregnancy or child bearing potential will be excluded from the study. end points of the study. the primary endpoint will be quantitative and qualitative measures of mtwa during n-3 pufas treatment compared to placebo. statistical analysis: quantitative differences in mtwa measurements will be analysed by a student's t-test and qualitative differences by a chi squared test. a probability of 0.05% will be considered significant.

Eligibility criteria:
inclusion criteria: * implantable cardiovertor defibrillators * microvolt twave alternans positive exclusion criteria: * unstable angina * chf

Keywords: fish oils
development of specific diagnostic tools for cardiac insufficiency with preserved ejection fraction

Conditions: Heart Failure

Summary: the mediagstole project aims to develop diagnostic tools for heart failure with preserved ejection fraction (ic / fep), a pathology that is difficult to diagnose and to manage clinically in the absence of targeted treatment . the ic / fep concerns the elderly population with comorbidities such as hypertension, obesity, anemia and atrial fibrillation. in the absence of specific biomarkers, clinical diagnosis is based on serum markers of heart failure with reduced ejection fraction (ic / fer). the identification of new biomarkers, genetic and / or cellular, specific for ic / fep would be an important innovation.


Eligibility criteria:
inclusion criteria group 1 (ejection fraction ≥ 50%) : * age \> or = 65, * heart failure (nt-probnp ≥ 450 pg/ml during hospitalization or follow-up) * echocardiography showing an ejection fraction ≥ 50%, * patients already hospitalized and followed in cardiology consultation, * patients agreeing to sign informed consent, * patient affiliated to french health care system. inclusion criteria group 2 (ejection fraction \< 50%) : * age \> or = 65, * heart failure (nt-probnp ≥ 450 pg/ml during hospitalization or follow-up) * echocardiography showing an ejection fraction \< 50%, * patients already hospitalized and followed in cardiology consultation, * patients agreeing to sign informed consent, * patient affiliated to french health care system. inclusion criteria group 3 (without heart failure) : * age \> or = 65, * patients already hospitalized and followed in cardiology consultation for one of the following pathology : stable coronaropathy without heart failure, arterial hypertension without heart failure, auricular fibrilation without heart failure * patients agreeing to sign informed consent, * patient affiliated to french health care system. exclusion criteria for all groups: * hemodynamic instability (cardiogenic shock), * any condition leading to a prognosis of less than 7 days, * known hepatocellular insufficiency, or known hepatic cirrhosis * asat / alat\> 10n excluding cardiac cause * any conditions that may put the patient at risk or increase the risk of non-compliance with the protocol or lost to follow-up according to the opinion of the investigator * patient under legal protection, under guardianship or under curatorship * inability to give the subject informed information * pregnant or breastfeeding woman

Keywords: heart failure (hf) progenitors cells biomarkers diastolic dysfunction
glyburide vs glucovance in the treatment of gdm

Conditions: Gestational Diabetes

Summary: a randomized comparison of glyburide to glucovance (metformin -glyburide) in the management of diabetes in pregnancy.

this study will be a randomized open label trial of glyburide compared to glucovance in the management of gestational diabetes. we hypothesize that glucovance will provide improved glycemic control and a lower failure rate with no increase in neonatal adverse outcomes. sixty-seven patients will be randomized by computer to each arm of the study. outcomes will be glycemic control, failure rate of the drug to achieve glycemic goals, and neonatal outcomes.

Eligibility criteria:
inclusion criteria: * gestational diabetes * pregnancy \> 12 weeks gestation * ability to give consent exclusion criteria: * inability to consent to the study * pre-existing diabetes * glucose-6-phosphate dehydrogenase (g6pd) deficiency * serum creatinine \>1 * liver disease * allergy to sulfa; * allergy to glyburide; * allergy to metformin; * fetal anomalies

Keywords: gestational diabetes, pregnancy, diabetes
integrative nutrition care plan for the patient with liver and colorectal cancer

Conditions: Malnutrition; Cancer of Colon; Cancer of Liver; Nutrition Aspect of Cancer

Summary: at present, the families of cancer patients are lack knowledge and experience of nutritional care after discharge. as a result, cancer patients often suffer from low nutritional status after being discharged from the hospital.

this study intends to design a home nutrition care plan to explore the effect of a home nutrition care plan on the nutritional status of patients with liver cancer and colorectal cancer at risk of malnutrition. malnutrition or side effects often lead to natural food intake for patients. it is not enough to meet the nutritional requirements, so it is matched with dietary products to help patients more easily meet their nutritional requirements. supplements are used to alleviate patients' side effects. it is hoped that they can help patients improve their nutritional status.

Eligibility criteria:
inclusion criteria: 1. patients with liver cancer or colorectal cancer stage i to iii 2. not suffering from other carcinomas in situ at the same time 3. will undergo surgery or non-surgical cancer treatment 4. can move, read and answer questions by itself 5. at least one social support (family or friend) to assist and support the patient to complete the trial 6. according to the apg-sga, the assessment score is between 4 \~ 9 7. the patient or caregiver can cooperate with the dietitian to track and answer related questions asked by the dietitian in a remote way through communication software or telephone every week. 8. able to adjust diet or take nutrition and supplements daily with the guidance of a nutritionist 9. be able to cooperate with doctors and the beginning of the study and monthly return visits and blood tests for health insurance items exclusion criteria: 1. perform organ transplantation or palliative care 2. hepatic encephalopathy 3. history of cardiovascular and cerebrovascular diseases 4. severe organ failure of the heart, breathing, or kidneys 5. history of digestive tract inflammation or ulcer 6. severe mental illness 7. an active infectious diseases 8. those who can only use intravenous nutrition and cannot use enteral nutrition 9. people who are allergic to product ingredients (milk, soy, or mango and their products) 10. unwilling to cooperate with dietitians to make dietary adjustments or supplement nutrition and supplements 11. unwilling to actively treat cancer

Keywords: nutrition care of cancer liver cancer colorectal cancer remote consultation nutrition supplement
idomeneo - is treatment reality in vascular medicine evidence-based and follows guideline recommendations? a project for quality development exemplified by peripheral arterial disease (pad)

Conditions: Symptomatic Peripheral Arterial Disease; Occlusive Disease of Artery of Lower Extremity; Quality of Life

Summary: the prevalence of peripheral arterial disease (pad) and the proportion of endovascular procedures for treatment are increasing worldwide. for many cases of treatment or procedures no randomized controlled trials (rct) or results from meta-analyses are so far available. the decision for treatment and selection of procedure is therefore not uncommonly left up to the personal expertise of the physician. the idomeneo study represents a multistage multimethodological project for healthcare research and quality assurance in interdisciplinary vascular medicine, which undertakes a comprehensive examination of this topic. various methods and data sources (even routine data) are linked in a meaningful way. the essential components of the total project are implementation of a register platform (germanvasc), which conforms to data protection and data security as well as the development of instruments for valid measurement of the quality of life of patients with pad. the data protection-conform linking of primary data in the register and routine data of the consortium partner barmer should also enable validation of the data sources.


Eligibility criteria:
inclusion criteria: * symptomatic peripheral artery disease (intermittent claudication or critical limb ischemia) * invasive treatment (open-surgical or endovascular) * informed consent was obtained exclusion criteria: * no informed consent was obtained * acute limb ischemia without any chronic symptomatic pad

Keywords: germanvasc peripheral arterial disease idomeneo routine data registry data data validity
post-marketing non-acute safety study in japan after severe acute respiratory syndrome coronavirus 2 (sars-cov-2) mrna-1273 covid-19 vaccine in persons at high risk of severe covid-19

Conditions: SARS-CoV-2

Summary: the goal of this study is to assess serious adverse events associated with hospitalizations in the non-acute phase after vaccination with the mrna-1273 vaccine in persons with underlying diseases who are considered to have a high risk of severe exacerbation of covid-19.

data collected from the jmdc claims database from may 2020 to october 2022.

Eligibility criteria:
inclusion criteria: * participants registered to receive the mrna-1273 vaccine in the pep up vaccination history database * participants who have a history of vaccination with the mrna-1273 vaccine in the pep-up vaccination history database and the observation start date is at least 6 months prior to vaccination with the mrna-1273 vaccine and have underlying diseases. exclusion criteria: * underlying diseases that were determined undetectable by the pre-screening of jmdc * participants who did not consent to the questionnaire.

Keywords: mrna-1273 mrna-1273 vaccine sars-cov-2 sars-cov-2 vaccine coronavirus virus diseases messenger rna covid-19 covid-19 vaccine moderna
physical therapy in shoulder impingement syndrome

Conditions: Subacromial Impingement Syndrome

Summary: the aim of this study is to evaluate the effects of low-level laser therapy (lllt) and therapeutic ultrasound combined with home-based exercise in comparison with home-based exercise alone in patients with subacromial impingement syndrome (sis). participants are going to evaluate before training, and at the 1-month follow-up and 3-month follow-up using the visual analog scale (vas) scores for pain during activity, at rest, and at night, and the shoulder pain and disability index (spadi).

sis is an important cause of pain and disability and affects activities of daily living. therefore, a major goal of sis treatment is to reduce pain and improve upper extremity function. in this prospective, randomized controlled, single-blind, interventional trial, a total of 60 patients with sis who met the eligibility criteria are going to enrolled in the study. eligible participants are going to randomly assign to one of the three groups by an independent blinded researcher, using a computer-generated random numbers and allocation ratio of 1:1:1: the lllt group (lg, n = 20), the ultrasound therapy group (ug, n = 20), and the control group (cg, n = 20). participants are going to evaluate before training, and at the 1-month follow-up and 3-month follow-up using the visual analog scale (vas) scores for pain during activity, at rest, and at night, and the shoulder pain and disability index (spadi).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of subacromial impingement syndrome based on physical examinations * persistent pain in one shoulder for at least 2 months * no passive shoulder range of motion limitations * failure of improvement in pain after analgesic medications exclusion criteria: * history of malignancy and systemic rheumatic diseases * evidence of systemic or local infection * presence of major trauma at the affected shoulder * history of shoulder surgery * rotator cuff lesions in the form of either calcific tendinosis or full-thickness tear as confirmed on mri scanning
an inpatient advance care planning intervention for older patients with hematologic malignancies

Conditions: Hematologic Malignancies

Summary: this is a pilot study to assess the preliminary efficacy of an inpatient advance care planning intervention on outcomes in older patients with hematologic malignancies

older adults with hematologic malignancies receive more aggressive inpatient care at the end of life compared to patients with solid tumors. advance care planning may promote early serious illness conversations for patients with hematologic malignancies, leading to less aggressive healthcare utilization at the end of life. this pilot aims to assess the preliminary efficacy of an inpatient advance care planning intervention on outcomes in older patients with hematologic malignancies.

Eligibility criteria:
inclusion criteria: * age ≥60 years * a diagnosis of hematologic malignancy \[including but not limited to acute leukemia, myeloid malignancies (e.g., atypical cml, mds/mpn overlap syndromes, cmml), multiple myeloma, lymphoma, or any other hematologic malignancies based on the primary oncologist's judgment\] * able to provide informed consent * being managed in the inpatient setting * english-speaking exclusion criteria: • none

Keywords: advance care planning intervention serious illness conversation hematologic malignancies
clinical and immunohisochemical evaluation of chemopreventive effect of thymoquinone on oral potentially malignant lesions.

Conditions: Premalignant Lesion

Summary: the present randomized, controlled, parallel-grouped trial includes 48 patients (aged 18 to 75 years) suffering from oral potential premalignant lesions. patients will be randomly assigned into 3 equal groups: group a: nigella sativa buccal tablets group 10mg group b: nigella sativa buccal tablets 5 mg group c:control group (placebo)

the present randomized, controlled, parallel-grouped trial included 48 patients (aged 18 to 75 years) suffering from oral potentially premalignant lesions. patients were randomly assigned into 3 equal groups: group a: nigella sativa buccal tablets group 10mg group b: nigella sativa buccal tablets 5 mg group c:control group (placebo)

Eligibility criteria:
inclusion criteria: inclusion criteria: * patients with age range 18-75 years. * patients with any known potentially malignant lesion confirmed histologically and clinically. exclusion criteria: * patients with systemic illness. * patients received previous treatment for the condition. * current malignancy. * pregnant or lactating women. * hypersensitivity to the intervention.
use of 3-d blood pool scintigraphy to guide left ventricular pacing lead placement in patients requiring cardiac resynchronization therapy

Conditions: Heart Failure; Left Ventricular Dysfunction; Cardiac Resynchronization Therapy

Summary: the purpose of this study is to determine whether multiple gated acquisition (muga) guided lead placement improves clinical outcomes for patients needing cardiac resynchronization therapy (crt) compared to traditional posterolateral left ventricular lead placement.

heart failure (hf) has a prevalence of five million individuals in the united states. approximately 25-30% of patients with hf due to left ventricular (lv) systolic dysfunction have prolonged qrs. prolonged qrs duration (\>120ms) on ecg in hf patients is associated with increased morbidity and mortality. delayed electrical activation of the lv translates to temporal delay in ventricular contraction. this is referred to as mechanical dyssynchrony. patients with advanced hf, low ejection fraction (ef) of less than 35% and qrs of more than 120ms are indicated for cardiac resynchronization therapy (crt). while most patients undergoing crt implantation show dramatic improvement in hf symptoms, 30-40% of the hf patients undergoing crt placement do not show a clinical response. the site of placement of the lv lead has been shown to be an important determinant of the effects of crt. measurement of left ventricular ejection fraction (lvef) is performed using non-invasive measures such as the muga. by using the available information on left ventricular systolic function the investigators plan on investigating the effects of muga-guided versus traditional lv lead placement for crt.

Eligibility criteria:
inclusion criteria: * male or female, 18 years or older * must have an approved indication for crt implantation * must have ischemic or nonischemic dilated cardiomyopathy * must have symptomatic hf with a new york association (nyha) classification of iii or iv * must be on optimal pharmacological therapy (this should include at the minimum, ace inhibitor and beta-blocker therapy as tolerated. * must have left ventricular ejection fraction (lvef) of ≤35% * must have ventricular conduction delay manifested as a qrs duration of \>120msec * must be able to provide informed consent for study participation and be willing to comply with follow-up tests and scheduled visits exclusion criteria: * hf diagnosis for less than 3 months * physical limitations to ambulation * life expectancy of less than six months * pregnant or planning for pregnancy in the next 6 months (must have a negative pregnancy test 7 days prior to enrollment)
glycemic and insulinemic impact of selected canadian beans

Conditions: Impaired Glucose Tolerance

Summary: the objective of this study is to compare the glycemic and insulinemic response elicited by ½ cup servings of 6 beans to those elicited by ½ cup servings of mashed potato, macaroni, rice and corn.

in order for a food to be able to claim a reduced glycemic response, it must be shown that a typical serving of the food elicits a significantly lower blood glucose responses compared to a serving of an appropriate control food. while many studies have examined the gi of beans, few studies have compared the glycemic impact of a typical serving of beans to a typical serving of other starchy foods. therefore, there are insufficient data to allow for a claim that beans have a low glycemic response. in addition, in order to make a claim of a reduced glycemic response, regulatory agencies also require that the insulinemic response to a food is not disproportionately increased.

Eligibility criteria:
inclusion criteria: * male or non-pregnant females, 18-75 years of age, inclusive * body mass index (bmi) \< 40 kg/m² * willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial and to refrain from smoking for 12hr prior to each visit. * normal fasting serum glucose (\<7.0mmol/l capillary corresponding to whole blood glucose \<6.3mmol/l). * understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator. exclusion criteria: * failure to meet any one of the inclusion criteria * known history of aids, hepatitis, diabetes or a heart condition * subjects using medications or with any condition which might, in the opinion of dr. wolever, the medical director of gi labs, either: 1) make participation dangerous to the subject or to others, or 2) affect the results. * major trauma or surgical event within 3 months of screening. * unwillingness or inability to comply with the experimental procedures and to follow gi labs safety guidelines. * known intolerance, sensitivity or allergy to any ingredients in the study products.

Keywords: pulses beans blood glucose insulin